GlassScriptPhysician profile
Lauren Atkinson
NPI 1063925246
$2,107.70
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.31 · 2022: $266 · 2023: $817 · 2024: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $703.98 | 2021-2024 | |
| Novo Nordisk INC | $465.17 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $158.19 | 2022-2024 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $155.96 | 2021-2024 | Jardiance, Emgality, Zepbound |
| Otsuka America Pharmaceutical, INC. | $95.90 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.87 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $67.74 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Corium, LLC | $51.34 | 2024 | Azstarys |
| Alkermes, INC. | $50.43 | 2023-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $42.51 | 2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $35.45 | 2022-2024 | Eliquis |
| Pfizer INC. | $33.58 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.74 | 2023-2024 | |
| Ironshore Pharmaceuticals INC. | $23.57 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.13 | 2024 | Caplyta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $22.63 | 2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $21.27 | 2023 | Aptima, Thinprep 2000 Processor |
| Dexcom, INC. | $18.79 | 2023 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $16.96 | 2024 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $13.49 | 2023 | Seglentis, Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.